Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
NCT ID: NCT00285428
Last Updated: 2021-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
82 participants
INTERVENTIONAL
2004-09-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
NCT03332121
Study of GS-4528 in Adults With Solid Tumors
NCT05840224
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849
Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma
NCT00307710
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
NCT00354926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose level 1
120 mg/m2
hA20-humanized anti-CD20 antibody
once weekly iv dosing for 4 weeks
Dose level 2
200 mg/m2
hA20-humanized anti-CD20 antibody
once weekly iv dosing for 4 weeks
Dose Level 3
375 mg/m2
hA20-humanized anti-CD20 antibody
once weekly iv dosing for 4 weeks
Dose level 1B
80 mg/m2
hA20-humanized anti-CD20 antibody
once weekly iv dosing for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hA20-humanized anti-CD20 antibody
once weekly iv dosing for 4 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Immunomedics, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Wegener, MD, PhD
Role: STUDY_CHAIR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York Presbyterian Hospital/Cornell Medical Center
New York, New York, United States
University Hospital of Pennsylvania
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. doi: 10.3109/10428191003672123.
Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. doi: 10.1200/JCO.2008.19.9117. Epub 2009 May 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM-T-hA20-01
Identifier Type: -
Identifier Source: org_study_id
NCT00112970
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.